Job titles of the future: Nature’s drug designer

In 2018, after nearly two decades working in Big Pharma, chemist Tim Cernak was ready to put his skills to a new use. 

For Merck, he’d developed precision therapies for cancer, HIV, and diabetes that could target disease while minimizing harm to healthy cells. But as a lifelong nature lover, he was increasingly concerned about the health of ecosystems and wondered whether his expertise could transfer. Animals, he learned, are often treated with pharmaceuticals formulated for humans, which affect them like old-school cancer drugs: Though intended to kill abnormal cells, they’re indiscriminate in the harm they cause. For instance, the standard of care for frogs infected with a deadly skin infection is itraconazole, an antifungal that is often lethal for the amphibian.

Cernak imagines a world where “the patient was always meant to be a frog in the first place, from the beginning to the end.” Now an associate professor at the University of Michigan, he’s worked on all types of creatures, from a Gila monster with a parasite to bald eagles with avian flu. Here’s what it takes to treat nature’s patients.

Experience with protein-modeling software 

Developing any type of drug is extremely expensive, failure-prone, and slow-going. But AI can speed up the entire drug-­design workflow, says Cernak. Google DeepMind’s AlphaFold model allows him to visualize a mutant protein’s three-­dimensional structure on a screen—rather than growing it on a plate, the traditional methodology—and then quickly generate possible new drugs that would latch onto that structure. The next step is to run a series of reactions and see which potential drugs may be effective; with the help of robots in the lab, he can speed through as many as 1,500 per day. 

Curiosity about creatures of all sizes

Cernak isn’t selective with his patients. For example, he worked on a treatment for loggerhead sea turtles after he was shocked to learn that the iconic species suffered from contagious tumors. He feels especially drawn to creatures that have helped humans, like the Gila monster, whose hormones have informed popular weight-loss drugs like Ozempic. And it’s not just animals; he’s also developing a precision insecticide to treat hemlock trees under attack from invasive species. 

A pioneering spirit

Cernak refers to this new discipline as “conservation chemistry.” It’s a combination of words with a loaded history, from DDT decimating US bald eagle populations in the 1960s, to cow painkillers killing millions of Indian vultures in the ’90s. He recognizes the risks, but Cernak feels that excluding chemists from conservation is a missed opportunity. 

“I’m just sick of looking at the chemical tools that are used in the conservation space, and they’re not cutting-edge,” he says. “It’s like, how do you have this super high-tech engine over here for making human medicines, while we’re living through a mass extinction?” 

Anna Gibbs is a journalist who covers the intersection between science and society.

STAT+: Scientists see promise in NIH proposal to cap number of grants they receive

Throughout Lawrence Tabak’s 25 years at the National Institutes of Health, serving first as the head of one of its institutes before becoming principal deputy director and subsequently acting director, he took many trips to universities around the country to talk to researchers. He made a point to prioritize state schools and smaller institutions. 

Never on those visits was there a shortage of researchers brimming with ideas they hoped would attract the funding to pursue. But without easy access to leaders within a field or top-of-the-line lab equipment, researchers outside top universities often struggle to compete for grants from the NIH.

“There was never an institution I went to that I wasn’t blown away by a few young people,” Tabak said. “But it made me upset, because I realized the maldistribution of resources was compromising their ability to reach their potential.” 

One proposal that’s been floated several times to help spread the wealth is to cap the number of grants individual researchers can receive from the NIH. Most recently, it was proposed in 2017 but was quickly walked back by the first Trump administration after pushback from high-rolling universities who would be harmed by the policy. 

Continue to STAT+ to read the full story…

Opinion: How long Covid’s scientific stalemate made it politically erasable

Mitchell Miglis had two months left. The Stanford University neurology professor had spent two years studying what long Covid does to the human nervous system — why patients’ hearts race when they stand, why their blood pressure collapses, why their bodies lose the ability to regulate themselves. His National Institutes of Health RECOVER grant was weeks from completion, data collected, analysis underway.

On March 25, 2025, a termination notice arrived. The grant was “incompatible with agency priorities.” No modification could bring it into alignment. “This is not only disappointing and demoralizing from a scientific perspective,” Miglis wrote in the Sick Times, a publication about long Covid, “but in a broader sense, as a clinician who sees these patients every day, a much larger disappointment to the patient community.”

Read the rest…

Diabetes association leader apologizes for expulsion of members, pledges to rebuild trust

Five days after five members of the American Diabetes Association were ushered out of its annual scientific sessions in New Orleans for handing out an editorial criticizing federal research cuts, ADA chief executive officer Charles Henderson on Wednesday apologized to the people expelled and to the broader diabetes community.

“First and foremost, I want to personally apologize to Dr. Steven Kahn, Dr. Desmond Schatz, Dr. Aaron Kelly, Dr. Maureen Gannon, and Dr. Justin Ryder, who were escorted out and denied access to scientific sessions, regardless of the circumstances that led to those events,” Henderson said in the three-minute video. “I recognize the impact that experience had on each of you. I am deeply sorry for the hurt, frustration, and the pain that resulted.”

Read the rest…